Aclaris Therapeutics (ACRS) FCF Margin (2017 - 2026)
Aclaris Therapeutics' (ACRS) quarterly FCF Margin came in at 912.27% in Q1 2026, down 1193.0% year-on-year from 83.47% in Q1 2025, and up 10.7% quarter-over-quarter from 1021.62% in Q4 2025.
Aclaris Therapeutics (ACRS) FCF Margin (2017 - 2026) Analysis & Trends
Aclaris Therapeutics' FCF Margin history runs 10 years deep, the most recent figure standing at 912.27% for Q1 2026.
- On a quarterly basis, FCF Margin fell 1193.0% year-over-year to 912.27% in Q1 2026; TTM through Mar 2026 was 625.47%, a 55602.0% decrease from a year earlier, with the FY2025 full-year figure at 603.42%, down 49554.0% from the prior year.
- FCF Margin climbed to 912.27% in Q1 2026 per ACRS's latest filing, from 1021.62% in the prior quarter.
- Across five years, FCF Margin topped out at 506.21% in Q3 2024 and bottomed at 1450.79% in Q1 2022.
- The 5-year median for FCF Margin is 563.53% (2025), against an average of 597.0%.
- Across the five-year window, FCF Margin surged 91049 bps in 2022 and plunged 92459 bps in 2025, its largest moves.
- Year by year, FCF Margin stood at 240.41% in 2022, then jumped by 82 bps to 43.79% in 2023, then plunged by 122 bps to 97.04% in 2024, then sank by 953 bps to 1021.62% in 2025, then gained by 11 bps to 912.27% in 2026.
- Per Business Quant, the three latest ACRS FCF Margin figures stand at 912.27% (Q1 2026), 1021.62% (Q4 2025), and 329.8% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Aclaris Therapeutics | 705.88 Mn | 705.88 Mn | 1.60 Mn | -912.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -912.27% |
| Dec 31, 2025 | -1,021.62% |
| Sep 30, 2025 | -329.80% |
| Jun 30, 2025 | -563.53% |
| Mar 31, 2025 | -900.34% |
| Dec 31, 2024 | -97.04% |
| Sep 30, 2024 | 506.21% |
| Jun 30, 2024 | -444.97% |
| Mar 31, 2024 | -873.64% |
| Dec 31, 2023 | -43.79% |
| Sep 30, 2023 | -264.37% |
| Jun 30, 2023 | -1,123.97% |
| Mar 31, 2023 | -1,044.07% |
| Dec 31, 2022 | -240.41% |
| Sep 30, 2022 | -41.89% |
| Jun 30, 2022 | -1,302.68% |
| Mar 31, 2022 | -1,450.79% |
| Dec 31, 2021 | -1,150.90% |
| Sep 30, 2021 | -642.68% |
| Jun 30, 2021 | -670.01% |